Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: Clinical and virological study in three patients

European Journal of Dermatology

Volumn 21, Issue 4, 2011, Pages 564-567

  Zanni, Martina ^a   Missale, Gabriele ^a   Santilli, Daniele ^a   Di Nuzzo, Sergio ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Anti TNF alpha; Etanercept; HCV; Psoriasis; Psoriatic arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; ETANERCEPT; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PROTEIN DETERMINATION; PSORIASIS; PSORIATIC ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; VIRUS LOAD;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; FEMALE; HEPATITIS C; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VIRAL LOAD;

EID: 80052981584     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1318     Document Type: Article

References (25)

1. Fabris P, Baldo V, Baldovin T, et al. Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol 2008; 42: 527-32.
2. Burrows NP, Norris PG, Alexander G, Wreghitt T. Chronic hepatitis C infection and psoriasis. Dermatology 1995; 190: 173.
3. Taglione E, Vatteroni ML, Martini P, et al. Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol 1999; 26: 370-2.
4. Palazzi C, Olivieri I, D'Amico E, et al. Hepatitis C virus infection in psoriatic arthritis. Arthritis Rheum 2005; 53: 223-5.
5. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-20.
6. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20: 757-90.
7. Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008; 35: 1944-9.
8. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat 2003; 14: 229-32.
9. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004; 51: 580-4.
10. Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 2006; 54: 361-2.
11. De Simone C, Paradisi A, Capizzi R, Carbone A, Siciliano M, Amerio PL. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006; 54: 1102-4.
12. Cecchi R, Bartoli L. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). Dermatol Online J 2006; 12: 4.
13. Linardaki G, Katsarou O, Ioannidou P, Karafoulidou A, Boki K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007; 34: 1353-5.
14. Cassano N, Vena GA. Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection. Int J Dermatol 2008; 47: 980-1.
15. Piccolo D, Di Cesare A, Fargnoli MC, Paoloni M, Vecchitti S, Peris K. Effective control of psoriasis by etanercept in a patient with HCV-related diseases. Eur J Dermatol 2008; 18: 459-60.
16. Alcaide AJ, Barrera MV, Habicheyn S, Lopez N, Mendiola MV, Herrera E. Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection. J Eur Acad Dermatol Venereol 2008; 22: 1514-6.
17. Collazo MH, Gonzalez JR, Torres EA. Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant. P R Health Sci J 2008; 27: 346-7.
18. Prignano F, Zanieri F, Milani S, Lotti T. Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report. Dermatol Ther 2009; 22: 386-90.
19. Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 2008; 8: 104-6.
20. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315-22.
21. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007; 56: 598-603.
22. Boetticher NC, Peine CJ, Kwo P, et al. A randomized, doubleblinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953-60.
23. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42: 2204-12.
24. Vauloup C, Krzysiek R, Greangeot-Keros L, et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 2006; 17: 290-3.
25. Marotte H, Fontanges E, Bailly F, Zoulim F, Trepo C, Miossec P. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology 2007; 46: 97-9.